We report here an analytical and clinical evaluation of the Stratus#{174} system in determining CK-MB in serum specimens. The Stratus assay procedure is based on radial immunopartition (3-7). In the CK-MB method, the solid phase consists of tabs of glass-fiber filter paper containing a pre-immobilized monoclonal anti-CK-MB antibody.
sion, Baxter Inc., Miami, FL 33152) appear elsewhere (8) .
No special modification of the instrument was required for the CK-MB assay.
Procedures

CK-MB determination.
We determined CK-MB by radial immunopartition, using the Stratus analyzer. The CK-MB fluorometric enzyme immunoassay kit (Dade) contains the following:
CK-MB antibody tabs. A solution of mouse monoclonal antibody specific for CK-MB is complexed onto the surface of glass-fiber filter paper by the addition of goat antibody specific for the Fe portion of mouse IgG.
Enzyme-labeled anti-CK. Calf intestinal alkaline phosphatase (EC 3.1.3.1) is covalently linked to mouse monoclonal anti-CK-BB Fab'. The conjugate is solubilized in 2-[(carbamoylmethyl)anuno]ethane sulfonic acid buffer (pH 7.0).
Substrate wash solution. The fluorogenic substrate consists of 4-methylumbelliferyl phosphate (1 mmol/L) in a diethanolamine buffer (pH 9.0). The cleavage of the phosphate group from 4-methylumbelliferyl phosphate, catalyzed by alkaline phosphatase, results in the production of 4-methylumbelliferone.
CK In some specimens, we also determined the CK-MB content after separation by discontinuous electrophoresis on polyacrylamide gel (Protean TM II Slab Cell; Bio-Rad Labs., Richmond, CA). We applied 20 L of serum and performed the electrophoresis at 4 #{176}C for 5 h at 400 V. The isoenzymes, made visible by specific CK staining, were measured densitometrically.
Total CK determination. We used an optimized spectrophotometric method (Enzyline#{174} CK NAC; BioM#{233}rieux, Lyon, France) to measure total CK at 37#{176}C (reference limits 0-120 UIL) with an automated analyzer (Eris 6170;
Olympus-Eppendorf, Hamburg, F.R.G.).
Evaluation
of imprecision. Two pools of fresh patients' sera (low-and high-concentration pools) were aliquoted and frozen, then assayed to evaluate within-run and be-tween-run precision. During this part of the study, we calibrated the Stratus system once a week.
Evaluation of linearity. Two serum samples with high CK-MB concentration were diluted (in successive twofold dilutions to a 64-fold dilution) with a serum poo1 containing no CK-MB (as confirmed by electrophoresis). The resulting samples, which covered the whole measuring range of CK-MB, were measured in duplicate.
Method comparisons. We collected 115 serum specimens from patients admitted to the University Hospital of Liege and for whom CK-MB had been requested on a routine basis. These specimens were assayed with the Stratus CK-MB method and with the comparison method.
Interference studies. Interference by hemoglobin was studied by adding increasing amounts of hemolysate to a serum specimen with low CK-MB content ( 
Clinical Evaluation
Healthy subjects.
We investigated 105 blood donors, 64 men (mean age ±SD: 43 ± 12 years) and 41 women (38 ± 9 years).
Acute myocardial infarction patients. We studied 18 patients, ages 30-69 years (mean 57, SD 9 years), who were admitted to the University Hospital, Liege, Belgium. AMI was diagnosed on the basis of a history of severe chest pain and electrocardiographic evidence of localized injury with typical ST-segment elevations. Total CK activity and CK-MB concentration were determined at admission, then every 4 h for 36 h and every 12 h thereafter until 72 h after admission. To determine the evolution of serum CK-MB after AMI in a homogeneous group of patients, we assayed samples from 11 subjects who had reached the coronary care unit within 4 h after the onset of the symptoms and whose total CK activities at admission were <150 UIL.
Seven of these patients had received a fibrinolytic therapy (with streptokinase); the other four were treated with intravenous heparmn. 
Results
Precision
Interference.
We saw no interference for hemoglobin concentrations up to 2.25 g/L. Acute myocardial infarction patients. We observed a typical increase and decrease pattern for serum total CK activities in the 11 patients with short delays in admission. Total CK peak activities ranged from 841 to 4140 UIL in the streptokinase-treated group (n = 7) and from 1421 to 2400 UIL in the patients who received intravenous heparin (n = 4).
For the streptokinase-treated patients, the mean CK-MB concentration in serum was 4.5 (SD 1.8) pgfL (mean ± SD) at admission, but increased rapidly during the following hours and averaged 97.9 pg/L 8 h after admission (Figure  1) . At peak (16 h after admission), CK-MB concentrations ranged from 38to 295 pg/L (mean 119, SD 94 pg/L). On day 3, the mean CK-MB concentration had decreased to 3.2 pgIL (range 0-9.7 pgfL). In the patients who received heparin, CK-MB reached its peak 20 h after admission, 4 h later than in the streptokinase-treated group. After heparm treatment, however, the amplitude of the changes was similar to those observed after fibrinolytic therapy, maximum concentrations ranging from 45 to 308 pg/L (mean 126, SD 103 pg/L). After 72 h, the heparin-treated patients 
DIscussIon
In this study, we investigated the analytical performance of the Stratus CK-MB method. Precision studies demonstrated within-run and between-run CVs <5.5% and 8.5%, Reference values determined by the Stratus technique for serum CK-MB were 0-6 jtg/L, which compares well with those obtained by others using an immunoenzymometric assay (9). Serial determinations performed in AMI patients showed the typical increase and decrease in CK-MB during the first 72 h after the attack. Within 24 h of admission, CK-MB increased to concentrations exceeding, on average, more than 20 times the upper limit of the reference interval. In most cases, the value had returned to 2 normal by day 3. Confirming previous results (11), CK-MB peaked earlier in the patients treated by streptokinase than in those who received heparin. The amplitude of the changes was, however, similar in the two groups of patients. In the patients investigated, the mean value of the CK-MB index, which expressed the CK-MB concentration as a percent of total CK activity, exceeded 4 during the first 32 h after admission.
In conclusion, we have validated a rapid, convenient radial partition immunoassay for CK-MB in serum and have demonstrated its clinical applicability when used at a coronary-care unit for diagnostic evaluation of AMI patients.
